Sara Seidelmann
Cardiovascular Disease · Greenwich, CTNPI 1710277843
Payments from drug & device makers
Across 129 payments — averaging $20.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$680
- AbbVie$525
- Pfizer$364
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$192
- Exact Sciences$139
- GSK$125
- plus $595 from 16 others
What the payments were for
- Food & beverage$2,619100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 33 | $680 |
| AbbVie | 23 | $525 |
| Pfizer | 18 | $364 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $192 |
| Exact Sciences | 4 | $139 |
| GSK | 7 | $125 |
| Merck | 6 | $120 |
| AstraZeneca | 7 | $109 |
| Kowa Pharmaceuticals America, Inc. | 4 | $52 |
| Phadia US Inc. | 2 | $36 |
| Amgen | 2 | $32 |
| CSL Behring | 1 | $30 |
| Genentech USA, Inc. | 2 | $29 |
| Antares Pharma, Inc. | 1 | $27 |
| Sanofi Pasteur Inc. | 2 | $26 |
| E.r. Squibb & Sons, L.L.C. | 1 | $25 |
| Halozyme Inc | 1 | $23 |
| Seqirus USA Inc | 1 | $21 |
| Boehringer Ingelheim | 1 | $19 |
| Novartis | 1 | $17 |
| Medtronic | 1 | $15 |
| Lilly USA, LLC | 1 | $14 |
How this compares
$2,619 in reported general payments places this provider in the 60th percentile of 415 cardiovascular disease providers in Connecticut.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 67 | $86,305 |
| EliquisApixaban | 29 | $49,003 |
| MounjaroTirzepatide | 25 | $33,713 |
| RybelsusSemaglutide | 15 | $23,903 |
| SynthroidLevothyroxine Sodium | 26 | $2,291 |
| Atorvastatin Calcium | 120 | $1,479 |
| Irbesartan | 60 | $1,439 |
| Levothyroxine Sodium | 61 | $1,245 |
| Rosuvastatin Calcium | 66 | $1,082 |
| Duloxetine Hcl | 13 | $908 |
| Pravastatin Sodium | 28 | $831 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 46 | $465 |
| Irbesartan-HydrochlorothiazideIrbesartan/Hydrochlorothiazide | 11 | $416 |
| Metoprolol Succinate | 15 | $336 |
| Allopurinol | 20 | $321 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $680 | $110,20882 claims |
| PfizerEliquis | $364 | $49,00329 claims |
| Lilly USA, LLCMounjaro | $14 | $33,71325 claims |
| AbbVieSynthroid | $525 | $2,29126 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 415 cardiovascular disease providers in Connecticut.
Other cardiovascular disease in Greenwich
- Glenn GandelmanGreenwich$165K
- Harlan KrumholzNew Haven$4M
- Jeffery TestaniNew Haven$3.4M
- Nihar DesaiNew Haven$3.2M
- Stuart ZarichBridgeport$1.3M
- John ForrestNew Haven$1.2M
- Hyung ChunNew Haven$1.1M
- Rohan KheraNew Haven$930K
- Brett NowlanBloomfield$798K
- Carlos Mena-HurtadoNew Haven$665K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.